Global Antibacterial Drugs In-Depth Industrial studies with Latest and Advance Market Trends, to 2022 - Vaccines Retain In-Depth Industrial studies with Latest and Advance Market Trends, Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance
 |
| Antibacterial Drugs |
Albany, New York, Mar 15, 2017
"Global
Antibacterial Drugs Market to 2022 - Vaccines Retain Market
Prominence While Pipeline Offers Innovative Approaches to Tackling
Antimicrobial Resistance"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
The
antibacterial drug market covers the drugs used in the prophylaxis
and treatment of bacterial infections. With a growing global concern
over antimicrobial resistance and its progressive growth, there is a
pronounced need for innovation within this market. This report
considers the key developments in this market, with particular focus
on drugs indicated for use in pneumonia, methicillin-resistant
staphylococcus aureus (MRSA), sepsis and tuberculosis.
Drugs
for the prevention of bacterial infections are typically vaccines,
which help to train the body’s immune system to fight off specific
infections, and can therefore help to prevent infections of certain
bacterial strains. However, several prophylactic monoclonal
antibodies are also currently in development.
Drugs for the treatment of bacterial infections
are slightly more varied. Most common are beta-lactam antibiotics,
which include the very widely prescribed penicillin. However,
bacteria have developed resistance to penicillin by producing
beta-lactamase enzymes that break open the beta-lactam ring found in
these antibiotics, rendering them ineffective. As a result modern
beta-lactams are frequently combination drugs of a beta-lactam and a
beta-lactamase inhibitor.
In addition to beta-lactams there are several
other classes of drugs used to treat bacterial infections. These
include fluoroquinolones, which inhibit DNA gyrase and/or
topoisomerase IV; and protein synthesis inhibitors, which have
applications within the treatment of bacteria that are resistant to
beta-lactam antibiotics. However, bacterial resistance has also
developed against these drugs, and as such there is a gap in the
market for a new generation of drugs that are effective against
drug-resistant bacteria.
The antibacterial market is currently dominated by
vaccines, in particular those for the prevention of pneumococcal
infections, diphtheria, tetanus and pertussis. However, recent years
have seen key additions in the form of therapies for
antibiotic-resistant bacteria, including strains with multi-drug
resistance. The number of such products is expected to increase
drastically between 2016 and 2022.
** Scope
Antibiotic resistance has caused a surge in the
development of antibiotics:
- How big is the antibiotic pipeline?
- How are companies attempting to overcome antibiotic resistance?
The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
- How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
- Will vaccines continue to drive market revenue?
The pipeline contains a range of molecular targets:
- Which molecular targets are most popular in the current pipeline?
- How many late-stage products are active against drug-resistant bacteria?
- What are the commercial prospects for the most promising late-stage pipeline products?
Big Pharma maintains a strong presence within the antibacterial drug market:
- Which of the leading companies are expected to have the highest share of the market by 2022?
- Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
- Which companies rely heavily of revenues derived from antibacterial drugs?
- How big is the antibiotic pipeline?
- How are companies attempting to overcome antibiotic resistance?
The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
- How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
- Will vaccines continue to drive market revenue?
The pipeline contains a range of molecular targets:
- Which molecular targets are most popular in the current pipeline?
- How many late-stage products are active against drug-resistant bacteria?
- What are the commercial prospects for the most promising late-stage pipeline products?
Big Pharma maintains a strong presence within the antibacterial drug market:
- Which of the leading companies are expected to have the highest share of the market by 2022?
- Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
- Which companies rely heavily of revenues derived from antibacterial drugs?
** Reasons to buy
- Understand the current clinical and commercial
landscape through a comprehensive analysis of innovation in the
antibacterial drug market in the context of the overall pipeline and
current market landscape. It also includes analysis of the deals
landscape, including both licensing deals and co-development deals.
Key indications covered in detail include pneumonia, MRSA, sepsis and
tuberculosis.
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the antibacterial pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at antibacterial drug clinical trials, to provide an insight into the risk associated with attempting to bring pipeline antibacterial drugs to market.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from antibacterial products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Assess the licensing and co-development deal landscape for antibacterial therapies.
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the antibacterial pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at antibacterial drug clinical trials, to provide an insight into the risk associated with attempting to bring pipeline antibacterial drugs to market.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from antibacterial products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Assess the licensing and co-development deal landscape for antibacterial therapies.
Comments
Post a Comment